Volatility speaks volumes

Log In | Sign Up



Hikma Pharmaceuticals

Selected Articles

2025-08-10
Yahoo Entertainment
One Hikma Pharmaceuticals Insider Raised Stake By 14% In Previous Year
2025-08-10
ETF Daily News
Hikma Pharmaceuticals (LON:HIK) Given New GBX 2,500 Price Target at JPMorgan Chase & Co.
2025-08-09
ETF Daily News
Hikma Pharmaceuticals (LON:HIK) Shares Down 7.1% After Analyst Downgrade
2025-08-09
ETF Daily News
Jefferies Financial Group Reaffirms "Buy" Rating for Hikma Pharmaceuticals (LON:HIK)
2025-08-09
ETF Daily News
Hikma Pharmaceuticals PLC (LON:HIK) Insider Mazen Darwazah Purchases 200,000 Shares
2025-08-07
The Irish Times
Trump-Putin summit boosts global stocks amid hopes of Ukraine ceasefire
2025-08-07
GlobeNewswire
Postoperative Pain Management Market Poised for Transformation During the Forecast Period (2025–2034) with Rising Non-Opioid Adoption | DelveInsight
2025-08-06
GlobeNewswire
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
2025-08-05
GlobeNewswire
Endocarditis Market Global and Regional Research Report 2025-2035 | AI and Molecular Diagnostics Set to Revolutionize Endocarditis Management
2025-08-05
GlobeNewswire
Cancer Pain Market Research Report 2025-2035 | Opioid-Sparing Regimens Gain Traction, AI-Driven Customization Enhancing Patient Outcomes

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom. GB00B0LCW083 www.hikma.com